About Donate Hours Maps & Floorplans Libraries A-Z

EBM Conference–Pediatrics

Dupilumab for Eosinophilic Esophagitis

Dupilumab for Eosinophilic Esophagitis

04/23/2024

Article:

Lancet Gastroenterol Hepatol. 2023 Nov;8(11):990-1004.

Efficacy and safety of dupilumab up to 52 weeks in adults and adolescents with eosinophilic oesophagitis (LIBERTY EoE TREET study): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Reviewer: Dr. Kelly Squires